O'Gorman Clodagh S M, O'Neill Michael B, Conwell Louise S
Graduate Entry Medical School, University of Limerick, Ireland, and Mid-Western Regional Hospital, Limerick, Ireland.
Vasc Health Risk Manag. 2010 Dec 20;7:1-14. doi: 10.2147/VHRM.S7356.
Children who appear healthy, even if they have one or more recognized cardiovascular risk factors, do not generally have outcomes of cardiovascular or other vascular disease during childhood. Historically, pediatric medicine has not aggressively screened for or treated cardiovascular risk factors in otherwise healthy children. However, studies such as the P-Day Study (Pathobiological Determinants of Atherosclerosis in Youth), and the Bogalusa Heart Study, indicate that healthy children at remarkably young ages can have evidence of significant atherosclerosis. With the increasing prevalence of pediatric obesity, can we expect more health problems related to the consequences of pediatric dyslipidemia, hypertriglyceridemia, and atherosclerosis in the future? For many years, medications have been available and used in adult populations to treat dyslipidemia. In recent years, reports of short-term safety of some of these medications in children have been published. However, none of these studies have detailed long-term follow-up, and therefore none have described potential late side-effects of early cholesterol-lowering therapy, or potential benefits in terms of reduction of or delay in cardiovascular or other vascular end-points. In 2007, the American Heart Association published a scientific statement on the use of cholesterol-lowering therapy in pediatric patients. In this review paper, we discuss some of the current literature on cholesterol-lowering therapy in children, including the statins that are currently available for use in children, and some of the cautions with using these and other cholesterol-lowering medications. A central tenet of this review is that medications are not a substitute for dietary and lifestyle interventions, and that even in children on cholesterol-lowering medications, physicians should take every opportunity to encourage children and their parents to make healthy diet and lifestyle choices.
看起来健康的儿童,即使有一个或多个已确认的心血管危险因素,在儿童期通常也不会出现心血管或其他血管疾病的后果。从历史上看,儿科医学并没有积极筛查或治疗其他方面健康的儿童的心血管危险因素。然而,诸如青少年动脉粥样硬化病理生物学决定因素研究(P-Day研究)和博加卢萨心脏研究等表明,非常年幼的健康儿童可能有明显动脉粥样硬化的证据。随着儿童肥胖症患病率的上升,我们能否预期未来会出现更多与儿童血脂异常、高甘油三酯血症和动脉粥样硬化后果相关的健康问题?多年来,已有药物可用于成人人群治疗血脂异常。近年来,已发表了其中一些药物在儿童中的短期安全性报告。然而,这些研究均未进行详细的长期随访,因此也没有描述早期降胆固醇治疗的潜在晚期副作用,或在降低或延迟心血管或其他血管终点方面的潜在益处。2007年,美国心脏协会发表了一份关于在儿科患者中使用降胆固醇治疗的科学声明。在这篇综述文章中,我们讨论了一些关于儿童降胆固醇治疗的当前文献,包括目前可用于儿童的他汀类药物,以及使用这些药物和其他降胆固醇药物的一些注意事项。本综述的一个核心原则是,药物不能替代饮食和生活方式干预,即使对于正在服用降胆固醇药物的儿童,医生也应抓住每一个机会鼓励儿童及其父母做出健康的饮食和生活方式选择。